Camurus AB (CAMX) NPV
Sell:607.00 SEKBuy:608.00 SEK
11.50 SEK
(1.94%)
- This stock can be held in a
Stocks and Shares ISA11.50 SEK
(1.94%)11.50 SEK
(1.94%)Company Information
About this company
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Key people
Key facts
- EPIC-
- LocationSweden
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINSE0007692850
- Market capSEK 34.97bn
- Employees249
- Shares in issue58.81m
- ExchangeStockholm Stock Exchange
- IndexSX All Share PI Market Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.